Lantern Pharma (LTRN) to Release Quarterly Earnings on Thursday

Lantern Pharma (NASDAQ:LTRN) is expected to be announcing its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect Lantern Pharma to post earnings of ($0.46) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 9:30 AM ET.

Lantern Pharma Trading Up 11.7%

LTRN stock opened at $2.87 on Thursday. Lantern Pharma has a 1-year low of $2.45 and a 1-year high of $5.74. The firm has a market cap of $32.09 million, a PE ratio of -1.64 and a beta of 1.55. The business’s 50-day moving average price is $3.14 and its two-hundred day moving average price is $3.68.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on LTRN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lantern Pharma in a research report on Monday, December 29th. Wall Street Zen raised shares of Lantern Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Lantern Pharma currently has a consensus rating of “Hold” and a consensus price target of $25.00.

Institutional Investors Weigh In On Lantern Pharma

Several hedge funds have recently modified their holdings of LTRN. Geode Capital Management LLC boosted its stake in shares of Lantern Pharma by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 96,742 shares of the company’s stock valued at $293,000 after purchasing an additional 4,661 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Lantern Pharma by 10.3% in the 4th quarter. Renaissance Technologies LLC now owns 110,400 shares of the company’s stock valued at $335,000 after buying an additional 10,300 shares during the last quarter. Cetera Investment Advisers bought a new position in Lantern Pharma in the 4th quarter valued at approximately $37,000. XTX Topco Ltd acquired a new stake in Lantern Pharma during the 2nd quarter worth approximately $40,000. Finally, CIBC Private Wealth Group LLC bought a new stake in Lantern Pharma during the 4th quarter worth approximately $47,000. Institutional investors and hedge funds own 28.62% of the company’s stock.

Lantern Pharma Company Profile

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.